Baird Financial Group
CRSP icon

Baird Financial Group’s CRISPR Therapeutics CRSP Stock Holding History

Baird Financial Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-29,575
Closed -$2.02M – 1770
2024
Q1 		$2.02M Buy
+29,575
New +$2.12M ﹤0.01% 953
2022
Q3 		– Sell
-3,895
Closed -$236K – 1724
2022
Q2 		$236K Buy
+3,895
New +$229K ﹤0.01% 1644
2021
Q4 		– Sell
-2,538
Closed -$284K – 1886
2021
Q3 		$284K Sell
2,538
-331
-12% -$41.6K ﹤0.01% 1692
2021
Q2 		$464K Sell
2,869
-203
-7% -$24.7K ﹤0.01% 1421
2021
Q1 		$374K Buy
3,072
+1,080
+54% +$163K ﹤0.01% 1446
2020
Q4 		$305K Buy
+1,992
New +$235K ﹤0.01% 1376

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baird Financial Group's CRSP Position: Q2 2024 in Review

Baird Financial Group sold out of CRISPR Therapeutics (CRSP) in Q2 2024, closing a stake of 29,575 shares — an estimated $2.02M sold.

Baird Financial Group first reported a position in CRSP in Q4 2020 and held it in 6 quarters. The position peaked at $2.02M in Q1 2024. 449 funds tracked by Wall St. Rank hold CRSP as of Q2 2024.

  • Baird Financial Group reported no remaining CRISPR Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Baird Financial Group sold 29,575 CRISPR Therapeutics shares in Q2 2024, an estimated $2.02M.
  • Baird Financial Group first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 6 quarters.
  • Baird Financial Group's CRISPR Therapeutics position peaked at $2.02M in Q1 2024.
  • 449 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2024.

Based on Baird Financial Group's 13F filing for Q2 2024, filed 14 Aug 2024.